Introduction / Background Preeclampsia is a serious pregnancy complication characterised by high blood pressure and signs of organ stress that develops after 20 weeks of pregnancy. Affecting 2-8% of pregnancies worldwide, it remains a leading cause of preventable maternal and infant deaths. The disease appears in two forms with different underlying causes: early-onset disease linked to placental problems, and late-onset disease connected to maternal health conditions. Both ty

Introduction / Background Gastric (stomach) cancer ranks as the fifth most common cancer worldwide and the third leading cause of cancer-related mortality. The disease is characterised by late-stage diagnosis and poor overall survival, with five-year survival rates below 35% in most populations. Most gastric cancers are adenocarcinomas that develop following years of chronic inflammation and progressive premalignant changes. Early identification of high-risk individuals and i

Perth, Western Australia - July 2, 2024: - Biotome Pty Ltd , a Western Australian biotechnology company, has been awarded an Innovation Booster Grant from the Western Australian Government's New Industries Fund . This grant will support the development and international patenting of Biotome's innovative preeclampsia risk test. The test, which uses novel peptide targets to detect specific antibodies in the blood, aims to provide early risk assessment for preeclampsia, a condi

Thursday, September 14th, 2022 - Perth, Australia: Biotome is part of an international consortium that has been awarded a grant from the Leducq Foundation for the Acute Rheumatic Fever Diagnosis Collaborative Network (ARC Network). The goal of this project is to discover biomarkers that accurately identify patients with acute rheumatic fever. Acute rheumatic fever [ARF] is a serious complication following a strep throat infection caused by Group A Streptococcus bacteria. It

Tuesday, July 5th, 2022 - Perth, Australia: Biotome has been awarded $497,000 in funding from the Western Australian Future Health Research & Innovation Fund , to develop their precision diagnostic for stomach cancer risk. This test will be the world’s first diagnostic for stomach cancer risk with high enough accuracy and a low enough cost to be used for public health screening. It has the potential to save thousands of lives in Australia, and millions around the world. Biot